A Phase III Randomized Study Of Oral Sapacitabine In Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Posted Date: May 15, 2019
- Investigator: Stephen Medlin
- Type of Study: Drug
The purpose of this study is to learn that among several drug options, which one is more likely to keep patients cancer in check as long as possible. This Phase III study assesses an experimental anti-cancer drug called sapacitabine and a marketed anti-cancer drug called decitabine. Decitabine has
Criteria:
To Be Eligible For This Study, Patients Must Have Acute Myeloid Leukemia (Aml)
Keywords:
Leukemia, Aml, Cancer, Hematology, Cyc682-12
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu